Compare AbCellera Biologics Inc (ABCL) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Stanley Black & Decker, Inc. — how do they compare? AbCellera Biologics Inc trades at $9.93 (market cap $2.99B), while Stanley Black & Decker, Inc. trades at $102.02 (market cap $15.71B). The key difference: Stanley Black & Decker, Inc. is far larger — about 5.3× AbCellera Biologics Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.23% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | SWK | |
|---|---|---|
Market Cap | $2.99B | $15.71B |
Sector | Health | — |
52-Week High | $9.76 | $104.00 |
52-Week Low | $2.78 | $62.12 |
Enterprise Value | $2.58B | $19.87B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
Stanley Black & Decker (SWK) trades at $102.64, down 1.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations with EPS of $1.57 versus $1.21 expected, driven by margin expansion and strong organic growth. The company announced a $1 billion U.S. investment plan to boost manufacturing and innovation, signaling strategic growth commitment.
The outlook is positive with improving profitability and debt reduction, but risks include competitive pressures and economic sensitivity. Analysts are mixed with a $93.67 consensus target below current price, suggesting cautious optimism. Upside hinges on continued execution of cost savings and market share gains in tools and infrastructure sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
